NEW YORK, NY / ACCESSWIRE / April 8, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merrimack Pharmaceuticals, Inc. (''Merrimack'' or the ''Company'') (NASDAQ: MACK).Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mack.
The investigation concerns whether Merrimackand certain of its officers and/or directors have violated federal securities laws.
On April 4, 2019, Merrimack announced the discontinuation of work on its sole drug candidate in clinical trials, MM-310, citing safety issues. Despite amending the protocol for its Phase 1 study after observing and disclosing signs of peripheral neuropathy in clinical trial participants beginning in November, Merrimack reported that subjects taking MM-310 continued to experience weakness, numbness and extremity pain associated with peripheral neuropathy. On this news, Merrimack's stock price fell sharply during intraday trading on April 5, 2019.
If you are aware of any facts relating to this investigation, or purchased Merrimackshares,you can assist this investigation by visiting the firm's site: www.bgandg.com/mack. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC